MX2009006105A - Dispersion solida que contiene revaprazan y proceso para su preparacion. - Google Patents

Dispersion solida que contiene revaprazan y proceso para su preparacion.

Info

Publication number
MX2009006105A
MX2009006105A MX2009006105A MX2009006105A MX2009006105A MX 2009006105 A MX2009006105 A MX 2009006105A MX 2009006105 A MX2009006105 A MX 2009006105A MX 2009006105 A MX2009006105 A MX 2009006105A MX 2009006105 A MX2009006105 A MX 2009006105A
Authority
MX
Mexico
Prior art keywords
solid dispersion
revaprazan
preparation
containing solid
preparing
Prior art date
Application number
MX2009006105A
Other languages
English (en)
Inventor
Young-Joon Park
Chang-Keun Hyun
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2009006105A publication Critical patent/MX2009006105A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención propone una dispersión sólida en la cual partículas de revaprazan se modifican en su superficie con un polímero soluble en agua, un sacárido soluble en agua, un agente tensoactivo o una mezcla de éstos, y un proceso para prepararla. La presente invención también proporciona una composición farmacéutica que contiene la dispersión sólida y un proceso para preparar la composición farmacéutica.
MX2009006105A 2006-12-22 2007-12-21 Dispersion solida que contiene revaprazan y proceso para su preparacion. MX2009006105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20060132722 2006-12-22
PCT/KR2007/006738 WO2008078922A1 (en) 2006-12-22 2007-12-21 Revaprazan-containing solid dispersion and process for the preparation thereof

Publications (1)

Publication Number Publication Date
MX2009006105A true MX2009006105A (es) 2009-06-18

Family

ID=39562674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006105A MX2009006105A (es) 2006-12-22 2007-12-21 Dispersion solida que contiene revaprazan y proceso para su preparacion.

Country Status (19)

Country Link
US (1) US8663658B2 (es)
EP (1) EP2101737B1 (es)
JP (1) JP5484910B2 (es)
KR (1) KR100954828B1 (es)
CN (1) CN101600419B (es)
AR (1) AR067084A1 (es)
AU (1) AU2007339080B2 (es)
BR (1) BRPI0720472A2 (es)
CA (1) CA2673536A1 (es)
ES (1) ES2496166T3 (es)
MX (1) MX2009006105A (es)
MY (1) MY146557A (es)
PA (1) PA8784701A1 (es)
PE (1) PE20090424A1 (es)
RU (1) RU2461382C2 (es)
SA (1) SA08290368B1 (es)
TW (1) TW200927124A (es)
WO (1) WO2008078922A1 (es)
ZA (1) ZA200905094B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200905094B (en) 2006-12-22 2010-09-29 Yuhan Corp Revaprazan-containing solid dispersion and process for the preparation thereof
CN101874775B (zh) * 2010-05-31 2013-03-13 沈阳药科大学 盐酸瑞伐拉赞纳米混悬剂及其制备方法
KR101739815B1 (ko) * 2010-12-01 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물
KR101739816B1 (ko) * 2010-12-01 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
KR101730865B1 (ko) * 2011-02-11 2017-04-27 주식회사유한양행 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
KR101739818B1 (ko) * 2011-05-20 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 현탁액 형태의 경구투여용 약학 조성물
KR101739820B1 (ko) 2012-03-28 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물
WO2015175505A1 (en) * 2014-05-15 2015-11-19 Lundbeck Llc Tetrabenazine modified release formulation
EP3157569B1 (en) * 2014-06-18 2019-07-24 F.Hoffmann-La Roche Ag New pharmaceutical composition comprising non-ionic surfactants
CN104825410A (zh) * 2015-05-04 2015-08-12 海南海力制药有限公司 一种盐酸瑞伐拉赞片及其制备方法
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN105288636B (zh) * 2015-12-11 2019-05-07 北京科莱博医药开发有限责任公司 增溶体系、固体分散体及药物制剂
US20200261365A1 (en) * 2015-12-16 2020-08-20 Merck Sharp & Dohme Corp. Process for preparing pharmaceutical compositions
CN105687150B (zh) * 2016-03-15 2019-12-10 常州市第四制药厂有限公司 一种盐酸瑞伐拉赞组合物及制备方法
CN106361721A (zh) * 2016-08-31 2017-02-01 佛山市弘泰药物研发有限公司 一种盐酸瑞伐拉赞胶囊及其制备方法
PT110585B (pt) * 2018-02-22 2021-04-22 Hovione Farmaciencia Sa Processo de produção contínua de partículas compreendendo secagem por atomização com preparação contínua da solução de atomização
WO2020261619A1 (ja) 2019-06-26 2020-12-30 株式会社リコー 医薬組成物
EP3989940A1 (en) 2019-06-26 2022-05-04 Ricoh Company, Ltd. Instantly soluble particle and method for producing the same
JP7777136B2 (ja) * 2020-12-18 2025-11-27 デウン ファーマシューティカル カンパニー リミテッド １－（５－（２，４－ジフルオロフェニル）－１－（（３－フルオロフェニル）スルホニル）－４－メトキシ－１ｈ－ピロール－３－イル）－ｎ－メチルメタンアミンを含む新規な経口投与用製剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05255125A (ja) 1992-02-29 1993-10-05 Upjohn Co:The 徐放性製剤およびその製法
JP2896532B2 (ja) 1994-08-13 1999-05-31 ユーハン コーポレーション 新規なピリミジン誘導体およびその製造方法
KR0157075B1 (ko) * 1994-08-13 1998-11-16 김태훈 신규의 피리미딘 유도체 및 그의 제조방법
EP0834314B1 (en) * 1995-06-12 2003-01-15 Ono Pharmaceutical Co., Ltd. Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast
US5955475A (en) 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
DK1227797T3 (da) 1999-11-12 2005-05-30 Abbott Lab Farmaceutiske faststofdispersionsformuleringer
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
AU7105501A (en) * 2000-07-17 2002-01-30 Yamanouchi Pharma Co Ltd Pharmaceutical composition improved in peroral absorbability
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE60100389T2 (de) 2001-07-11 2004-05-19 Apr Applied Pharma Research S.A. Fettlösliche Substanzen enthaltende Granulate und Verfahren zu ihrer Herstellung
CA2472419A1 (en) * 2002-01-11 2003-07-24 Takeda Chemical Industries, Ltd. Coumarin derivatives, process for their production and use thereof
WO2004060352A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
CA2546115C (en) * 2003-11-14 2013-01-08 Ajinomoto Co., Inc. Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US7776873B2 (en) 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
ZA200905094B (en) 2006-12-22 2010-09-29 Yuhan Corp Revaprazan-containing solid dispersion and process for the preparation thereof

Also Published As

Publication number Publication date
US8663658B2 (en) 2014-03-04
ES2496166T3 (es) 2014-09-18
CA2673536A1 (en) 2008-07-03
PA8784701A1 (es) 2009-07-23
CN101600419A (zh) 2009-12-09
WO2008078922A1 (en) 2008-07-03
JP5484910B2 (ja) 2014-05-07
EP2101737A4 (en) 2013-05-01
AR067084A1 (es) 2009-09-30
CN101600419B (zh) 2012-05-09
JP2010513474A (ja) 2010-04-30
AU2007339080B2 (en) 2012-09-27
MY146557A (en) 2012-08-30
TW200927124A (en) 2009-07-01
SA08290368B1 (ar) 2011-10-08
AU2007339080A1 (en) 2008-07-03
EP2101737B1 (en) 2014-06-18
KR100954828B1 (ko) 2010-04-27
HK1138517A1 (en) 2010-08-27
RU2461382C2 (ru) 2012-09-20
ZA200905094B (en) 2010-09-29
US20100041688A1 (en) 2010-02-18
KR20080059083A (ko) 2008-06-26
EP2101737A1 (en) 2009-09-23
BRPI0720472A2 (pt) 2014-01-14
RU2009128206A (ru) 2011-01-27
PE20090424A1 (es) 2009-05-15

Similar Documents

Publication Publication Date Title
MY146557A (en) Revaprazan-containing solid dispersion and process for the preparation thereof
TW200745261A (en) Aqueous dispersions based on nitrocellulose-polyurethane particles
WO2007150030A3 (en) Microfluidic synthesis of organic nanoparticles
MX2009004547A (es) Proceso para producir dispersiones de poliol.
WO2008064351A3 (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2008030567A3 (en) Dry powder compound formulations and uses thereof
BRPI0818358A2 (pt) Processo para a preparação de uma dispersão aquosa de partículas, dispersão aquosa de partículas de compósito, uso de uma dispersão aquosa de partículas de compósito, e, pó de partícula de compósito
IL208744A0 (en) Nucleic acid-lipid particles, compositions comprising the same and uses thereof
WO2007143204A3 (en) Compositions and methods for modifying cell surface glycans
WO2009076676A3 (en) Compositions and methods for producing isoprene
BRPI0818911A2 (pt) Composição, processo para a preparação de bronze de hidrogênio e tungstênio ou de uma composição de bronze de hidrogênio e tungstênio, dispersão de partícula, e, uso de partículas de bronze de hidrogênio e tungstênio ou de partículas que contenham bronze de hidrogênio e tungstênio
WO2007127841A3 (en) Compositions and methods of preparation thereof
WO2006128937A3 (es) Nanoparticulas que comprenden quitosano y ciclodextrina
WO2008008917A3 (en) Hydroxyapatite particles
WO2007002007A3 (en) Methods and compositions for expressing a heterologous protease
WO2007136552A3 (en) Compatibilized polymer processing additives
IL196426A0 (en) Microparticulates based on an amphiphilic copolymer, processes for the preparation thereof and pharmaceutical compositions containing the same
IL186127A (en) Subcutaneous preparations for the treatment of depression and methods for their preparation
WO2007076370A3 (en) Block copolymer particles
EP2442642A4 (en) STABILIZED BIOZIDE DISPERSION BY SUBMIKRONIZED CARRIER PARTICLES, METHOD FOR THE PRODUCTION AND COMPOSITION THEREOF
EP2245091A4 (en) Nanoparticle dispersion, compositions containing the same, and articles made therefrom
WO2008062467A3 (en) Cultured melanocytes on biopolymers
WO2008112277A3 (en) Compositions and methods for treating cancer
WO2009022108A3 (en) Hydrogen storage material
WO2006100578A3 (en) Nano-metal particle-containing polymer composites, methods for producing same, and uses for same